

ASX Announcement and Media Release

31 October 2003

SciGen Limited

SCI GEN'S QUARTERLY CASH FLOW STATEMENT- APPENDIX 4C

SciGen Limited has released its September 2003 Quarterly Cashflow Statement (Appendix 4C) to the market.

Cash receipts from customers were A\$785,000 for the 3 months to 30 September 2003. This was down on the June quarter number due to timing differences with some significant orders which were placed towards the end of the quarter. Actual sales in the September quarter were 49% higher than those recorded for the 3 months to June 2003, which is a pleasing result.

In terms of the current quarter, in addition to usual operating expenditure the company expects to make a payment of an annual license fee instalment to Biotechnology General Corporation of US\$1.3M by 31 December 2003. This is the second of three total payments for licensing rights and is a budgeted expense.

About SciGen

SciGen Ltd is registering a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in

conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singaporean biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO

Telephone: +61 2 9234 1700

Web: www.scigen.com.au